We are analyzing https://link.springer.com/article/10.1007/s10549-015-3316-4.

Title:
Revisiting the estrogen receptor pathway and its role in endocrine therapy for postmenopausal women with estrogen receptor-positive metastatic breast cancer | Breast Cancer Research and Treatment
Description:
Endocrine therapy (ET) is the most commonly administered first-line systemic therapy for estrogen receptor-positive (ER+) metastatic breast cancer (MBC). Manipulation of hormone levels was one of the earliest ET approaches. However, treatment modalities have since evolved with the growing understanding of estrogen biosynthesis and ER biology. The current armamentarium of ET includes selective estrogen receptor modulation, aromatase inhibition, and selective estrogen receptor downregulation. However, intrinsic or acquired resistance to ET is frequently observed. Significant strides have been made in recent years in our understanding of the mechanisms of resistance to ET, and several targeted approaches including inhibitors against the phosphatidylinositol 3-kinase/mammalian target of rapamycin (PI3K/mTOR) pathway and cyclin-dependent kinase 4/6 (CDK4/6) have shown great promise. The mTOR inhibitor, everolimus, is already in clinical use for the treatment of resistant ER+MBC. However, multiple levels of evidence indicate that ER signaling remains as an important therapeutic target even in the resistance setting, providing the rationale for sequencing multiple lines and combinations of ET. In addition, recurrent mutations in estrogen receptor 1 (ESR1), the gene that encodes the ER, have been identified in the genomic studies of metastatic ER+ breast cancer. ESR1 mutations are an important mechanism for acquired resistance, and effective ER targeting in this setting is particularly important.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Health & Fitness
Education
Science

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We can't figure out the monetization strategy.

Many websites are intended to earn money, but some serve to share ideas or build connections. Websites exist for all kinds of purposes. This might be one of them. Link.springer.com could be secretly minting cash, but we can't detect the process.

Keywords {🔍}

cancer, pubmed, google, scholar, breast, article, cas, estrogen, therapy, clin, central, endocrine, postmenopausal, oncol, advanced, receptor, fulvestrant, treatment, receptorpositive, kinase, cell, anastrozole, women, resistance, aromatase, res, study, tamoxifen, firstline, inhibitors, mol, versus, phase, metastatic, hormone, randomized, human, adjuvant, cyclin, trial, results, clinical, biol, pathway, abstract, survival, exemestane, patients, research, cyclindependent,

Topics {✒️}

/news/press-release/press-release-detail/pfizer_receives_u_s_fda_accelerated_approval_of_ibrance_palbociclib /publications/targeted-therapies-cancer/2013/april-2013/pi3k-inhibitors hormone-receptor-positive locally advanced month download article/chapter er/her2-positive breast cancer phosphatidylinositol 3-kinase/akt-mediated activation org/professionals/physician_gls/pdf/breast future endocrine therapies hormone-resistant breast cancer breast-cancer-derived xenografts estrogen-induced cyclin d1 er-positive breast cancer cyclin-dependent kinase activity estrogen receptor-mediated effects er+ breast cancer caused gov/ct2/show/nct01602380 gov/ct2/show/nct01953588 hormone receptor–positive hormone receptor-positive patient-level meta-analysis cancer genome atlas estrogen receptor alpha estrogen receptor-positive metastatic breast cancer constitutively active akt-3 full article pdf human breast tumours cyclin-dependent kinase 4/6 cyclin-dependent kinase phosphatidylinositol 3-kinase/mammalian target early breast cancer randomized confirm trial randomized trial comparing phase iii study estrogen-induced activation advanced breast cancer human breast cancers estrogen induces early complete cross-resistance estrogen receptor pathways important therapeutic target overcoming endocrine resistance 105th annual meeting advanced breast carcinoma estrogen receptor pathway prior endocrine therapy privacy choices/manage cookies robertson jfr anti-estrogen resistance breast cancer cells

Questions {❓}

Bedard PL, Freedman OC, Howell A, Clemons M (2008) Overcoming endocrine resistance in breast cancer: are signal transduction inhibitors the answer?
Fry MJ (2001) Phosphoinositide 3-kinase signalling in breast cancer: how big a role might it play?
Johnston SR, Yeo B (2014) The optimal duration of adjuvant endocrine therapy for early stage breast cancer–with what drugs and for how long?
Miller WR, Bartlett J, Brodie AMH et al (2008) Aromatase inhibitors: are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter?
Muss HB (2014) Adjuvant chemotherapy in older women with breast cancer: who and what?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Revisiting the estrogen receptor pathway and its role in endocrine therapy for postmenopausal women with estrogen receptor-positive metastatic breast cancer
         description:Endocrine therapy (ET) is the most commonly administered first-line systemic therapy for estrogen receptor-positive (ER+) metastatic breast cancer (MBC). Manipulation of hormone levels was one of the earliest ET approaches. However, treatment modalities have since evolved with the growing understanding of estrogen biosynthesis and ER biology. The current armamentarium of ET includes selective estrogen receptor modulation, aromatase inhibition, and selective estrogen receptor downregulation. However, intrinsic or acquired resistance to ET is frequently observed. Significant strides have been made in recent years in our understanding of the mechanisms of resistance to ET, and several targeted approaches including inhibitors against the phosphatidylinositol 3-kinase/mammalian target of rapamycin (PI3K/mTOR) pathway and cyclin-dependent kinase 4/6 (CDK4/6) have shown great promise. The mTOR inhibitor, everolimus, is already in clinical use for the treatment of resistant ER+MBC. However, multiple levels of evidence indicate that ER signaling remains as an important therapeutic target even in the resistance setting, providing the rationale for sequencing multiple lines and combinations of ET. In addition, recurrent mutations in estrogen receptor 1 (ESR1), the gene that encodes the ER, have been identified in the genomic studies of metastatic ER+ breast cancer. ESR1 mutations are an important mechanism for acquired resistance, and effective ER targeting in this setting is particularly important.
         datePublished:2015-03-12T00:00:00Z
         dateModified:2015-03-12T00:00:00Z
         pageStart:231
         pageEnd:242
         sameAs:https://doi.org/10.1007/s10549-015-3316-4
         keywords:
            Metastatic breast cancer
            Endocrine therapy
            Estrogen receptor
            Resistance
            Oncology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-015-3316-4/MediaObjects/10549_2015_3316_Fig1_HTML.gif
         isPartOf:
            name:Breast Cancer Research and Treatment
            issn:
               1573-7217
               0167-6806
            volumeNumber:150
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer US
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Gayathri Nagaraj
               affiliation:
                     name:Loma Linda University
                     address:
                        name:Division of Medical Oncology & Hematology, Department of Medicine, Loma Linda University, Loma Linda, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Cynthia Ma
               affiliation:
                     name:Washington University School of Medicine
                     address:
                        name:Division of Oncology, Washington University School of Medicine, St. Louis, USA
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Revisiting the estrogen receptor pathway and its role in endocrine therapy for postmenopausal women with estrogen receptor-positive metastatic breast cancer
      description:Endocrine therapy (ET) is the most commonly administered first-line systemic therapy for estrogen receptor-positive (ER+) metastatic breast cancer (MBC). Manipulation of hormone levels was one of the earliest ET approaches. However, treatment modalities have since evolved with the growing understanding of estrogen biosynthesis and ER biology. The current armamentarium of ET includes selective estrogen receptor modulation, aromatase inhibition, and selective estrogen receptor downregulation. However, intrinsic or acquired resistance to ET is frequently observed. Significant strides have been made in recent years in our understanding of the mechanisms of resistance to ET, and several targeted approaches including inhibitors against the phosphatidylinositol 3-kinase/mammalian target of rapamycin (PI3K/mTOR) pathway and cyclin-dependent kinase 4/6 (CDK4/6) have shown great promise. The mTOR inhibitor, everolimus, is already in clinical use for the treatment of resistant ER+MBC. However, multiple levels of evidence indicate that ER signaling remains as an important therapeutic target even in the resistance setting, providing the rationale for sequencing multiple lines and combinations of ET. In addition, recurrent mutations in estrogen receptor 1 (ESR1), the gene that encodes the ER, have been identified in the genomic studies of metastatic ER+ breast cancer. ESR1 mutations are an important mechanism for acquired resistance, and effective ER targeting in this setting is particularly important.
      datePublished:2015-03-12T00:00:00Z
      dateModified:2015-03-12T00:00:00Z
      pageStart:231
      pageEnd:242
      sameAs:https://doi.org/10.1007/s10549-015-3316-4
      keywords:
         Metastatic breast cancer
         Endocrine therapy
         Estrogen receptor
         Resistance
         Oncology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-015-3316-4/MediaObjects/10549_2015_3316_Fig1_HTML.gif
      isPartOf:
         name:Breast Cancer Research and Treatment
         issn:
            1573-7217
            0167-6806
         volumeNumber:150
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer US
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Gayathri Nagaraj
            affiliation:
                  name:Loma Linda University
                  address:
                     name:Division of Medical Oncology & Hematology, Department of Medicine, Loma Linda University, Loma Linda, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Cynthia Ma
            affiliation:
                  name:Washington University School of Medicine
                  address:
                     name:Division of Oncology, Washington University School of Medicine, St. Louis, USA
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Breast Cancer Research and Treatment
      issn:
         1573-7217
         0167-6806
      volumeNumber:150
Organization:
      name:Springer US
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Loma Linda University
      address:
         name:Division of Medical Oncology & Hematology, Department of Medicine, Loma Linda University, Loma Linda, USA
         type:PostalAddress
      name:Washington University School of Medicine
      address:
         name:Division of Oncology, Washington University School of Medicine, St. Louis, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Gayathri Nagaraj
      affiliation:
            name:Loma Linda University
            address:
               name:Division of Medical Oncology & Hematology, Department of Medicine, Loma Linda University, Loma Linda, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Cynthia Ma
      affiliation:
            name:Washington University School of Medicine
            address:
               name:Division of Oncology, Washington University School of Medicine, St. Louis, USA
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Division of Medical Oncology & Hematology, Department of Medicine, Loma Linda University, Loma Linda, USA
      name:Division of Oncology, Washington University School of Medicine, St. Louis, USA
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(313)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.64s.

LINK . SPRINGER . COM {}